Welcome to our dedicated page for Lakewood-Amedex news (Ticker: LABT), a resource for investors and traders seeking the latest updates and insights on Lakewood-Amedex stock.
Lakewood-Amedex Biotherapeutics reports developments tied to its clinical-stage antimicrobial pipeline and public-company status. News items cover the Bisphosphocin® class, antimicrobial resistance data for the lead compound Nu-3, and the company’s development work for infected diabetic foot ulcers, with additional platform references to complicated urinary tract infection and pulmonary infections.
Company updates also include Nasdaq listing activity under the LABT symbol and governance changes following its direct listing. These announcements describe the company’s transition into a Nasdaq-traded biotechnology issuer while continuing to center on its proprietary antimicrobial platform.
Lakewood-Amedex Biotherapeutics (NASDAQ: LABT) expanded its global IP portfolio for lead candidate Nu-3, a Bisphosphocin antimicrobial gel for mildly infected diabetic foot ulcers. Two new patents in Australia and New Zealand bring the Nu-3 gel formulation total to 27 granted patents across major regions.
The company now holds 71 granted patents and 28 pending, supporting advancement of Nu-3 into a Phase 2 clinical trial and reinforcing protection of its Bisphosphocin platform worldwide.
Lakewood-Amedex Biotherapeutics (NASDAQ: LABT) reported positive data supporting advancement of its lead antimicrobial candidate Nu-3 for mildly infected diabetic foot ulcers. The company completed key formulation, delivery and cGMP manufacturing steps, improved cost of goods, and generated multikilogram gel supplies suitable for a planned Phase 2 clinical trial.
Nu-3 drug substance shows at least five-year stability, while the gel formulation is stable for at least two years with undetectable bioburden and no added preservatives.
Lakewood-Amedex Biotherapeutics (NASDAQ: LABT) signed an agreement with Professional Education and Research Institute (PERI) to act as CRO for the Phase 2 clinical program of Nu-3, a Bisphosphocin antimicrobial for mildly infected diabetic foot ulcers (iDFU).
The program starts with a single-blinded Phase 2a study testing 2%, 5% and 10% gel concentrations, followed by a planned Phase 2b study comparing different dosing regimens versus placebo in this large, underserved market.
Lakewood-Amedex Biotherapeutics (NASDAQ: LABT) reported positive in vitro antimicrobial resistance (AMR) data for lead candidate Nu-3, a topical Bisphosphocin class compound for infected diabetic foot ulcers (iDFU). In 21-day serial‑passage studies, Nu-3 showed only slight MIC increase for E. coli and no MIC change for MRSA, while ciprofloxacin controls rose >2,000-fold (E. coli) and >600-fold (MRSA). Nu-3 retained activity against ciprofloxacin‑resistant isolates, supporting a low potential for resistance development and broad-spectrum activity against resistant pathogens.
Lakewood-Amedex Biotherapeutics (NASDAQ: LABT) appointed Joseph Tucker, Ph.D., CEO of Enveric Biosciences (NASDAQ: ENVB), to its Board of Directors on April 28, 2026. The appointment follows Lakewood-Amedex's recent Nasdaq direct listing and is positioned to strengthen governance and strategic capabilities as the company advances its Bisphosphocin® program, including lead candidate Nu-3 for infected diabetic foot ulcers.
Dr. Tucker brings more than two decades of biotech leadership, experience with public listings, M&A, and capital raises, including having raised over $100 million and advancing Enveric's EB-003 toward an anticipated first-in-human trial.
Lakewood-Amedex Biotherapeutics (NASDAQ: LABT) announced its common stock began trading on the Nasdaq Capital Market on April 23, 2026 under the ticker LABT. The company is a clinical-stage biotechnology developer of the Bisphosphocin® class and named Nu-3 as its lead product for infected diabetic foot ulcers (iDFU).
Management said it plans to initiate a Phase 2a clinical trial in iDFU shortly and cited the large U.S. diabetes population and concerns about antibiotic-resistant bacterial strains as drivers for development.